Klaus Charissé

11.0k citations

56 papers · 3.9k indexed · 2 hit papers · h-index 30

Co-authors: Muthiah Manoharan Martin A. Maier William Querbes Daniel G. Anderson Chang G. Peng Kallanthottathil G. Rajeev Muthusamy Jayaraman Anna Borodovsky
Topics: RNA Interference and Gene Delivery (43 papers)Advanced biosensing and bioanalysis techniques (26 papers)DNA and Nucleic Acid Chemistry (17 papers)
Cited by: Molecular Biology Cancer Research Biomaterials
Journals: Journal of the American Chemical Society Nucleic Acids Research Angewandte Chemie International Edition
Partner nations: United States Germany Netherlands

In The Last Decade

Klaus Charissé

56 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery

2012 1.0k citations Alfica Sehgal, William Querbes et al. profile →
Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown

2015 517 citations Klaus Charissé, Muthiah Manoharan et al. profile →

Peers

Countries citing papers authored by Klaus Charissé

Since Specialization

Citations

This map shows the geographic impact of Klaus Charissé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klaus Charissé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klaus Charissé more than expected).

Fields of papers citing papers by Klaus Charissé

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klaus Charissé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klaus Charissé. The network helps show where Klaus Charissé may publish in the future.

Co-authorship network of co-authors of Klaus Charissé

This figure shows the co-authorship network connecting the top 25 collaborators of Klaus Charissé. A scholar is included among the top collaborators of Klaus Charissé based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klaus Charissé. Klaus Charissé is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Expanding Conjugate Space of RNAi Therapeutics: Ligand at the 3′ End of the Antisense Strand Achieves Uncompromised In Vivo Potency and Efficacy and Reveals Interactions with the Argonaute-2 PAZ Domain 2025 ·Journal of Medicinal Chemistry ·(unknown),Dhrubajyoti Datta,Christopher R. Brown,Jason A. Gilbert,Amy Chan,Jennifer L. S. Willoughby,Swati Gupta,(unknown),(unknown),Tim Racie,Li Lei,Mark K. Schlegel,Adam Castoreno,Klaus Charissé,Kallanthottathil G. Rajeev,Martin Egli,Muthiah Manoharan	3
2	Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors 2023 ·Journal of Controlled Release ·(unknown),Süleyman Can Öztürk,Hamdullah Yanık,Ece Tavukçuoğlu,Adem Şahin,Dhrubajyoti Datta,Klaus Charissé,(unknown),Marı́a Isabel Loza,Alfonso Calvo,Einar Sulheim,(unknown),Geir Klinkenberg,Ruth Schmid,Muthiah Manoharan,Güneş Esendağlı,Marı́a José Alonso	57
3	Role of a “Magic” Methyl: 2′-Deoxy-2′-α-F-2′-β-C-methyl Pyrimidine Nucleotides Modulate RNA Interference Activity through Synergy with 5′-Phosphate Mimics and Mitigation of Off-Target Effects 2022 ·Journal of the American Chemical Society ·Dale C. Guenther,S. Mori,Shigeo Matsuda,Jason A. Gilbert,Jennifer L. S. Willoughby,(unknown),Anna Bisbe,Yongfeng Jiang,Saket Agarwal,(unknown),Maja M. Janas,Klaus Charissé,Martin A. Maier,Martin Egli,Muthiah Manoharan	21
4	Efficient Downregulation of Alk4 in Skeletal Muscle After Systemic Treatment with Conjugated siRNAs in a Mouse Model for Duchenne Muscular Dystrophy 2022 ·Nucleic Acid Therapeutics ·(unknown),(unknown),(unknown),Rubina Parmar,Klaus Charissé,Laura Sepp‐Lorenzino,Muthiah Manoharan,Annemieke Aartsma‐Rus,Maaike van Putten	11
5	Overcoming GNA/RNA base-pairing limitations using isonucleotides improves the pharmacodynamic activity of ESC+ GalNAc-siRNAs 2021 ·Nucleic Acids Research ·Mark K. Schlegel,Shigeo Matsuda,Christopher R. Brown,Joel M. Harp,Joseph D. Barry,(unknown),Adam Castoreno,Sally Schofield,(unknown),Muthiah Manoharan,Klaus Charissé,Martin Egli,Martin A. Maier	19
6	Chirality matters: stereo-defined phosphorothioate linkages at the termini of small interfering RNAs improve pharmacology in vivo 2021 ·Nucleic Acids Research ·(unknown),Nate Taneja,Jennifer L. S. Willoughby,(unknown),Christopher R. Brown,Tuyen Nguyen,Anna Bisbe,Shigeo Matsuda,(unknown),Rajar M. Manoharan,Kallanthottathil G. Rajeev,Martin A. Maier,Ivan Zlatev,Klaus Charissé,Martin Egli,Muthiah Manoharan	55
7	5′-Morpholino modification of the sense strand of an siRNA makes it a more effective passenger 2019 ·Chemical Communications ·Pawan Kumar,Rubina Parmar,Christopher R. Brown,Jennifer L. S. Willoughby,Donald J. Foster,I. Ramesh Babu,Sally Schofield,Vasant Jadhav,Klaus Charissé,Jayaprakash K. Nair,Kallanthottathil G. Rajeev,Martin A. Maier,Martin Egli,Muthiah Manoharan	29
8	Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis 2019 ·Molecular Therapy — Methods & Clinical Development ·Linda L. Kusner,Kristina Yucius,Manjistha Sengupta,Andrew Sprague,(unknown),Tuyen Nguyen,Klaus Charissé,Satya Kuchimanchi,(unknown),Kevin Fitzgerald,Henry J. Kaminski,Anna Borodovsky	42
9	Structural basis for the synergy of 4′- and 2′-modifications on siRNA nuclease resistance, thermal stability and RNAi activity 2018 ·Nucleic Acids Research ·Joel M. Harp,Dale C. Guenther,Anna Bisbe,Lydia A. Perkins,Shigeo Matsuda,Gopal R. Bommineni,Ivan Zlatev,Donald J. Foster,Nate Taneja,Klaus Charissé,Martin A. Maier,Kallanthottathil G. Rajeev,Muthiah Manoharan,Martin Egli	37
10	Chirality Dependent Potency Enhancement and Structural Impact of Glycol Nucleic Acid Modification on siRNA 2017 ·Journal of the American Chemical Society ·Mark K. Schlegel,Donald J. Foster,Alexander V. Kel’in,Ivan Zlatev,Anna Bisbe,Muthusamy Jayaraman,Jeremy G. Lackey,Kallanthottathil G. Rajeev,Klaus Charissé,Joel M. Harp,Pradeep S. Pallan,Martin A. Maier,Martin Egli,Muthiah Manoharan	62
11	Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression 2017 ·Molecular Therapy ·Jennifer L. S. Willoughby,Amy Chan,Alfica Sehgal,James S. Butler,Jayaprakash K. Nair,Tim Racie,Svetlana Shulga‐Morskaya,Tuyen Nguyen,Kun Qian,Kristina Yucius,Klaus Charissé,Theo J.C. van Berkel,Muthiah Manoharan,Kallanthottathil G. Rajeev,Martin A. Maier,Vasant Jadhav,Tracy Zimmermann	86
12	Hepatocyte‐Specific Delivery of siRNAs Conjugated to Novel Non‐nucleosidic Trivalent N‐Acetylgalactosamine Elicits Robust Gene Silencing in Vivo 2015 ·ChemBioChem ·Kallanthottathil G. Rajeev,Jayaprakash K. Nair,Muthusamy Jayaraman,Klaus Charissé,Nate Taneja,Jonathan O′Shea,Jennifer L. S. Willoughby,Kristina Yucius,Tuyen Nguyen,Svetlana Shulga‐Morskaya,Stuart Milstein,Abigail Liebow,William Querbes,Anna Borodovsky,Kevin Fitzgerald,Martin A. Maier,Muthiah Manoharan	148
13	Abstract 15574: A Subcutaneous Platform for RNAi Therapeutics Targeting ANGPTL3 2013 ·Circulation ·William Querbes,Scott Barros,Renta Hutabarat,Stuart Milstein,(unknown),Satya Kuchimanchi,Klaus Charissé,Rachel A. Myers,Muthiah Manoharan,Martin A. Maier,Kevin Fitzgerald	1
14	Intravesical Delivery of Small Activating RNA Formulated into Lipid Nanoparticles Inhibits Orthotopic Bladder Tumor Growth 2012 ·Cancer Research ·Moo Rim Kang,Glen Yang,Robert F. Place,Klaus Charissé,Hila Epstein-Barash,Muthiah Manoharan,Long‐Cheng Li	87
15	An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment 2012 ·Journal of Visualized Experiments ·Moo Rim Kang,Glen Yang,Klaus Charissé,Hila Epstein-Barash,Muthiah Manoharan,Long-Cheng Li	11
16	Formulation of Small Activating RNA Into Lipidoid Nanoparticles Inhibits Xenograft Prostate Tumor Growth by Inducing p21 Expression 2012 ·Molecular Therapy — Nucleic Acids ·Robert F. Place,Ji Wang,Emily J. Noonan,Rachel Meyers,Muthiah Manoharan,Klaus Charissé,(unknown),Vera Huang,Xiaoling Wang,Long‐Cheng Li	48
17	Unique Gene‐Silencing and Structural Properties of 2′‐Fluoro‐Modified siRNAs 2011 ·Angewandte Chemie International Edition ·Muthiah Manoharan,Akin Akinc,Rajendra K. Pandey,June Qin,Philipp Hadwiger,Matthias John,(unknown),Klaus Charissé,Martin A. Maier,Lubomir V. Nechev,Emily M. Greene,Pradeep S. Pallan,Eriks Rozners,Kallanthottathil G. Rajeev,Martin Egli	154
18	Reversed-phase high-performance liquid chromatography method for simultaneous analysis of two liposome-formulated short interfering RNA duplexes 2010 ·Analytical Biochemistry ·(unknown),(unknown),Gary Lavine,Klaus Charissé,Muthiah Manoharan	13
19	Effect of chemical modifications on modulation of gene expression by duplex antigene RNAs that are complementary to non-coding transcripts at gene promoters 2010 ·Nucleic Acids Research ·Jonathan K. Watts,Dongbo Yu,Klaus Charissé,(unknown),Pierre Potìer,Muthiah Manoharan,David R. Corey	33
20	In vivo silencing of alpha-synuclein using naked siRNA 2008 ·Molecular Neurodegeneration ·Jada Lewis,Heather L. Melrose,David Bumcrot,Andrew Hope,Cynthia Zehr,Sarah Lincoln,Adam Braithwaite,Zhen He,(unknown),Kelly M. Hinkle,Caroline Kent,Ivanka Toudjarska,Klaus Charissé,Ravi Braich,Rajendra K. Pandey,Michael G. Heckman,Demetrius M. Maraganore,Julia E. Crook,Matthew J. Farrer	112

About Klaus Charissé

Klaus Charissé is a scholar working on Molecular Biology, Cancer Research and Biotechnology, having authored 56 papers that have together received 3.9k indexed citations. Recurring topics across this work include RNA Interference and Gene Delivery (43 papers), Advanced biosensing and bioanalysis techniques (26 papers) and DNA and Nucleic Acid Chemistry (17 papers). The work is most often cited by research in Molecular Biology (3.4k citations), Cancer Research (606 citations) and Biomaterials (263 citations). Klaus Charissé has collaborated with scholars based in United States, Germany and Netherlands. Frequent co-authors include Muthiah Manoharan, Martin A. Maier, William Querbes, Daniel G. Anderson, Chang G. Peng, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, Anna Borodovsky, Alfica Sehgal and Róbert Langer. Their work appears in journals such as Journal of the American Chemical Society, Nucleic Acids Research and Angewandte Chemie International Edition.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact